How are high burden countries implementing policies and tools for latent tuberculosis infection? A survey of current practices and barriers

This survey of HBCs shows limited implementation of LTBI guidelines, and provides some insight into barriers to implementation, including shortage of products (eg, PPD), high costs (eg, IGRAs), and lack of regulatory approval of newer treatments (eg, rifapentine).


Faust Health Sc Rep 2020.pdf (1.3 MB)